Compare

IGF-1 LR3 vs TB-500 Fragment

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

IGF-1 LR3

764 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 68% · Mixed 16% · Unfavorable overall 16%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Mood
-117
Focus
-162
Sleep quality
-145
Lean mass
-166
Joint comfort
-101

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Fatigue
-21
Nausea
-83
Water retention
0
Appetite loss
10
Injection site reaction
-101

Self-reported dose per injection

Median bucket: 100–200 mcg · Most common: 100–200 mcg

Reports span 25–600 mcg

25–50
2
50–100
13
100–200
22
200–400
11
400–600
2

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing48stacking31side effects34igf-1 lr322

How repeat users are trending

Among repeat reporters, 63% said they felt similar to their last entry, 42% more positive, and 18% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 28 days · Based on 168 repeat reporters

TB-500 Fragment

1497 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 51% · Mixed 32% · Unfavorable overall 17%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Focus
156
Sleep quality
30
Lean mass
59
Joint comfort
175
Recovery
122

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Nausea
72
Water retention
109
Appetite loss
24
Injection site reaction
171
Anxiety
121

Self-reported dose per injection

Median bucket: 200–400 mcg · Most common: 200–400 mcg

Reports span 25–1000 mcg

25–50
2
50–100
5
100–200
10
200–400
20
400–600
15
600–1000
9

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing21stacking19side effects17tb-500 fragment30

How repeat users are trending

Among repeat reporters, 61% said they felt similar to their last entry, 43% more positive, and 21% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 23 days · Based on 329 repeat reporters

Sources (7)

Published sources linked on the IGF-1 LR3 and TB-500 Fragment wiki pages.

  1. PubMed

    Insulin-like growth factor-I and its binding proteins in sport and exercise medicine

    Baxter RC. Endocr Rev. 2011

    Source
    Wiki study page →
  2. ClinicalTrials.gov

    IGF-1 LR3 studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  3. PubMed

    Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice

    Engel MG, Narayan S, Cui MH, et al. Journal of Alzheimer's disease : JAD. 2025

    Source
    Wiki study page →
  4. PubMed

    Revolutionary decellularized Alstroemeria stem-based nerve conduit integrated with GelMA and controlled IGF-1 LR3 release for enhanced rat sciatic nerve regeneration

    Yavuz E, Sağır MS, Ercan A, et al. International journal of biological macromolecules. 2025

    Source
    Wiki study page →
  5. PubMed

    Thymosin beta4: a multi-functional regenerative peptide (review)

    Goldstein AL, Kleinman HK. Ann N Y Acad Sci. 2012

    Source
    Wiki study page →
  6. PubMed

    Thymosin beta 4 and wound healing: a multifunctional peptide

    Goldstein AL, Kleinman HK. Expert Opin Biol Ther. 2010

    Source
    Wiki study page →
  7. PubMed

    Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance

    Mendias CL, Awan TM. Sports medicine (Auckland, N.Z.). 2026

    Source
    Wiki study page →